Osteoarthritis Pain is an indication for drug development with over 70 pipeline drugs currently active. According to GlobalData, preregistered drugs for Osteoarthritis Pain have a 66.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Osteoarthritis Pain compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Osteoarthritis Pain overview

Osteoarthritis pain, the hallmark symptom of this degenerative joint disease, arises from the breakdown of cartilage, leading to bone-on-bone friction, inflammation, and structural changes in the affected joints. Typically occurring in weight-bearing joints like the knees, hips, and spine, it manifests as stiffness, swelling, and reduced mobility, severely impacting daily activities. While age, genetics, and lifestyle factors contribute to its development, there’s no cure for osteoarthritis. Management focuses on alleviating pain and improving function through a combination of non-pharmacological interventions like exercise, weight management, and assistive devices, along with pharmacotherapy such as analgesics, NSAIDs, and intra-articular injections.

For a complete picture of PTSR and LoA scores for drugs in Osteoarthritis Pain, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.